FolioStart writing free

Psychology · Literature

Research papers on Psilocybin-assisted therapy for depression

Recent and highly-cited academic work on psilocybin-assisted therapy for depression, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →Or track new psilocybin-assisted therapy for depression papers automatically as they publish
  1. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

    R. Murphy, H. Kettner, R. Zeifman, et al. · 2022 · Frontiers in Pharmacology · 210 citations

    Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; however, its role has never been formally assessed in a trial of psychedelic-assisted therapy. We aimed to investigate the relationships between therapeutic alliance and rapport, the quality of the acute psychedelic experience and treatment outcomes. Methods: This 2-arm double-blind randomized controlled trial compared escitalopram with psychedelic-assisted therapy for moderate-severe depressive disorder (N = 59). This analysis focused on the psilocybin condition (n = 30), who received two oral doses of 25 mg psilocybin, 3-weeks apart, with psychologi

    Save this paper
  2. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

    Adam W. Levin, R. Lancelotta, N. Sepeda, et al. · 2024 · PLOS ONE · 83 citations

    We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. In a randomized, waiting list-controlled clinical trial for major depressive disorder in adults (N = 24), participants were randomized to an immediate (N = 13) or delayed (N = 11) condition with two oral doses of psilocybin (20mg/70kg and 30mg/70kg). Ratings of therapeutic alliance significantly increased from the final preparation session to one-week post-intervention (p = .03, d = .43). A stronger total alliance at the final

    Save this paper
  3. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial

    Jordan Sloshower, R. Zeifman, Jeffrey R. Guss, et al. · 2024 · Scientific Reports · 68 citations

    Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic effects. However, no psychedelic trials to date have substantiated this finding in a clinical sample. In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with moderate to severe MDD were administered placebo (n = 19) followed by psilocybin (0.3 mg/kg) (n = 15) 4 weeks later.

    Save this paper
  4. Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.

    B. Pagni, R. Zeifman, S. Mennenga, et al. · 2025 · The American journal of psychiatry · 27 citations

    OBJECTIVE Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking. METHODS Eighty-four adults with AUD were randomized to two medication sessions of either psilocybin (N=44) or active placebo (diphenhydramine; N=40), received 12 weekly psych

    Save this paper
  5. In the New Era of Psychedelic Assisted Therapy: A Systematic Review of Study Methodology in Randomized Controlled Trials

    Paul S Soliman, D. Curley, Christy Capone, et al. · 2024 · Psychopharmacology · 22 citations

    Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy methamphetamine [MDMA]), and classical psychedelics (e.g. psilocybin, lysergic acid diethylamide [LSD], and N,N-dimethyltryptamine [DMT/ayahuasca]) in conjunction with assisted therapy (AT) for psychiatric disorders. A notable methodological challenge in psychedelic AT, however, is the complexity of blinding procedures. The lack of efficacious blinding can introduce considerable response bias, reduce internal validity, and compromise participant retention. This systematic review examines design and blinding techniques in RCTs utilizing psychedelic

    Save this paper
  6. Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial.

    Margaret Ross, R. Iyer, Martin L. Williams, et al. · 2025 · General hospital psychiatry · 20 citations

    IMPORTANCE Psilocybin-assisted psychotherapy may offer a novel approach to treating depression, anxiety, and existential distress in individuals with life threatening illnesses, where current treatments show limited efficacy. OBJECTIVE To evaluate the efficacy and safety of psilocybin-assisted psychotherapy versus active placebo and psychotherapy in adults with life-threatening illnesses. DESIGN Double-blind, randomized controlled phase 2b trial (RCT) with an open-label extension and 6-month follow-up (January 2020 - October 2023). SETTING Single-site study at a tertiary hospital's palliative care department (St. Vincent's Hospital Melbourne affiliated with the University of Melbourne)

    Save this paper
  7. Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis

    V. Menon, Parthasarathy Ramamurthy, Sandesh Venu, et al. · 2024 · Acta Psychiatrica Scandinavica · 17 citations

    There is growing interest in the use of psychedelic‐assisted therapy (PAT) for major depressive disorder (MDD), including treatment‐resistant depression. We used randomized controlled trial (RCT) data to compare summary estimates of change in depression ratings with PAT versus comparator treatments in MDD. We also compared response and remission rates, and adverse effects.

    Save this paper
  8. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

    Benjamin R. Lewis, J. Hendrick, Kevin Byrne, et al. · 2025 · PLOS Medicine · 15 citations

    Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR versus MBSR alone for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. We hypothesized that psilocybin would augment the antidepressant effects of MBSR in this population. Methods and findings We conducted a randomized controlled trial that enroll

    Save this paper
  9. Psilocybin for depression: Considerations for clinical trial design

    Kelley C. O’Donnell, Sarah E. Mennenga, Michael P. Bogenschutz · 2019 · Journal of Psychedelic Studies · 14 citations

    Background and aims: Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols to study this question systematically. Given the subjective quality of both the psychedelic experience and depressive symptomatology, great care must be taken when designing a protocol to study the clinical efficacy of psychedelic drugs. This study will discuss many factors to consider when designing a clinical trial of psilocybin for M

    Save this paper
  10. Psychedelic-assisted therapy: An overview for the internist

    B. Barnett, E. Mauney, Franklin King · 2025 · Cleveland Clinic Journal of Medicine · 13 citations

    Preliminary evidence suggests that psychedelic-assisted therapy—the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin—may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA). However, in August 2024, the FDA declined to approve a New Drug Application for MDMA and asked its sponsor to conduct another phase 3 trial. Clinicians are urged to prepare for the possible return of psychedelics to m

    Save this paper
  11. Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial

    Laetitia Vanderijst, Felix Hever, A. Buot, et al. · 2024 · BMC Psychiatry · 11 citations

    A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical efficacy of psilocybin-assisted therapy when incorporated as an auxiliary intervention during inpatient rehabilitation for severe alcohol use disorder. Moreover, it intends to pinpoint the modifications in the two core neurocognitive systems underscored by dual-process models of addiction. In this doubl

    Save this paper
  12. Treating comorbid insomnia in patients enrolled in therapist-assisted transdiagnostic internet-delivered cognitive behaviour therapy for anxiety and depression: A randomized controlled trial

    M. Edmonds, V. Peynenburg, V. Kaldo, et al. · 2024 · Internet Interventions · 9 citations

    Transdiagnostic Internet-delivered cognitive behaviour therapy (ICBT) for patients experiencing anxiety and depression can produce large improvements in symptoms. Comorbid insomnia is common among individuals seeking treatment for anxiety and depression, yet transdiagnostic ICBT rarely targets insomnia and many ICBT patients report that symptoms of insomnia remain after treatment. This trial explored the impact of including a brief intervention for insomnia alongside an existing transdiagnostic ICBT course that included brief weekly therapist assistance. Patients were randomly assigned to receive either the Standard transdiagnostic (n = 75) or a Sleep-Enhanced course (n = 142), which include

    Save this paper
  13. Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

    Anthony Back, Susanna Myers, John Guy, et al. · 2024 · Psychedelic Medicine · 7 citations

    For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into a new version of guidelines. In this Technical Report, we describe our evolving guidelines specifying acceptable practices for facilitator use of touch to ensure a safe, supportive, and therapeutic participant experience. Our primary goal with these guidelines is to create a haptic experience during t

    Save this paper
  14. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

    J. Rucker, T. Mantingh, Jess Kerr-Gaffney, et al. · 2026 · Nature Medicine · 5 citations

    Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health Service (NHS) site in England. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for major depressive disorder and had an inadequate response to ≥2 antidepressant treatments or ≥1 antidepressant plus ≥1 psychotherapy. Participants received 25-mg

    Save this paper
  15. Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy

    Faith Ekoh, Shanice Rerrie, James Angud, et al. · 2025 · Psychoactives · 4 citations

    Today’s research highlights the therapeutic potential of the hallucinogen psilocybin in the treatment of pathologies associated with mood, cognitive, and affective dysregulation. These domains of function are regulated by the serotonergic system, which can be influenced by sex hormones, like estrogen and testosterone, and psychedelic compounds including psilocybin. Current evidence supports a higher prevalence of affective disorders in females, and a growing awareness of sex-based differences in response to drug therapy. Estrogen’s influence on serotonin physiology is an aspect that must be accounted for when planning a treatment regimen that includes a psychoactive drug such as psilocybin.

    Save this paper
  16. Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder

    Noah D. Gold, Broc A. Pagni, Petros D. Petridis, et al. · 2025 · Psychedelic Medicine · 4 citations

    Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed relationships between value changes, acute psilocybin experiences, and drinking outcomes. Methods: In a phase II clinical trial (NCT02061293), 93 participants with AUD received 12 weeks of treatment, including manualized psychotherapy and two 8-h drug administration sessions with either psilocybin ( n = 48)

    Save this paper
  17. Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study

    Matthew Hicks, Olivia Hicks, Ryan Bradley, et al. · 2026 · Journal of Psychedelic Studies · 3 citations

    Background and aims: Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. This study was designed to test the feasibility of conducting group psilocybin therapy in low-income adults with depression in Oregon's regulated psilocybin program. Methods: An open label, uncontrolled design was used. After a medical screening visit, participants were enrolled in cohorts of six. Each cohort participated in two 90-min preparation sessions conducted online followed by two psilocybin administration sessions one week apart where they consumed dehydrated and homogenized whole mushrooms, Psilocybe cubensis (B+ strain) prepared in a tea. Two d

    Save this paper
  18. Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients

    L. Belinger, F. Moujaes, R. von Rotz, et al. · 2026 · Philosophical Transactions of the Royal Society B: Biological Sciences · 1 citations

    Abstract Psychedelic-assisted therapy, particularly with psilocybin, is increasingly proposed as a treatment for major depressive disorder, yet the neural and psychological mechanisms underlying its effects remain under investigation. In a randomized, double-blind, placebo-controlled clinical trial, individuals diagnosed with major depressive disorder received a single, moderate dose of psilocybin (0.215 mg kg−1) or placebo, with the same psychological support. We analysed N = 37 individuals with major depressive disorder undergoing assessments of depressive symptoms (Beck's depression inventory and Montgomery–Åsberg depression rating scale), self-concept (Frankfurt self-concept scale) and n

    Save this paper
  19. Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.

    Danica E. Johnson, Shakila Meshkat, Erica S. Kaczmarek, et al. · 2025 · Progress in neuro-psychopharmacology & biological psychiatry · 1 citations

    BACKGROUND Cognitive difficulties within treatment-resistant unipolar and bipolar depression (TRD; TRBD) often do not improve with conventional pharmacotherapies. Psilocybin-assisted psychotherapy (PAP) has shown promise as a novel intervention for TRD; however, few studies have assessed its effects on cognition in this population. METHODS This retrospective post hoc analysis included 26 adults with TRD or TRBD from an open-label trial of PAP. Cognition was assessed with the Digit Symbol Substitution Test (DSST) and Trail Making Test Part A and B (TMT-A/B) at baseline, one-day, and two-weeks post-treatment. Linear mixed models (LMMs) evaluated change over time, and reliable change indices

    Save this paper
  20. Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.

    C. O'Callaghan, Voula Kallianis, Margaret Ross · 2026 · Journal of music therapy

    Limited evidence supports treatment for distress in life-threatening illness. Psychedelic-assisted psychotherapy (PAP) may help. Despite music's presence in PAP, sparse accounts of music-related experiences exist. Such research is needed to optimize music's presence within PAP. This qualitative analysis aimed to understand participants' music-related accounts of their PAP experiences within a randomized controlled trial (RCT) for depression and anxiety associated with life-threatening illness, and participants' perceived mechanisms of change attributed to music during PAP. Participants undergoing an 11-session, manualized PAP RCT (with open-label extension) engaged in semi-structured intervi

    Save this paper
  21. Internet-assisted cognitive behavioral therapy with telephone coaching versus an educational control for antenatal depression: protocol for a randomized controlled trial with population-based screening

    A. Sourander, T. Korpilahti-Leino, T. Ristkari, et al. · 2025 · Frontiers in Psychiatry

    Background Up to 15% of pregnant women suffer from antenatal depression, and there is mounting evidence that the consequences can be devastating for both the woman and her child. Identifying effective treatments is crucial to avoiding the harmful consequences of unrecognized and untreated depression. Methods This ongoing research project evaluates the efficacy of the Stronger Together internet-assisted cognitive behavioral therapy (iCBT) with telephone coaching for antenatal depression. It is a large, population-based, two-parallel group, randomized controlled trial. The overarching hypothesis is that iCBT programs are easy to access and affordable and will reduce self-reported symptoms of a

    Save this paper
  22. Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trial.

    B. Pagni, S. Ross, S. Mennenga, et al. · 2026 · Drug and alcohol dependence

    BACKGROUND Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). It remains unknown, however, whether patients derive additional benefit when psilocybin is administered open-label after completion of blinded treatment. Here, we report safety and efficacy outcomes from an open-label extension of a Phase II RCT of PAT for AUD (NCT02061293). METHODS Fifty-nine adults with AUD received a single open-label administration of psilocybin (25-40mg/70kg) accompanied by four hours of manualized therapy. During the preceding double-blind phase, 29 of these participants had received psilocybin (psilocybin-psilocybin group; PP) and 30

    Save this paper
  23. Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial

    C. Sayalı, E. Weisman, F. Barrett · 2026

    Background. Change in cognitive control is a candidate transdiagnostic mechanism of psychedelic therapy. One account predicts that, once acute effects resolve, psilocybin shifts control toward flexibility while sparing inhibition and working memory. A motivational account (PRISM) predicts that psilocybin increases the willingness to exert control rather than the ability to do so. We tested both in patients with co-occurring alcohol use disorder (AUD) and major depression. Methods. In this secondary analysis of a randomized, double-blind, placebo-controlled trial of psilocybin for AUD with comorbid major depressive disorder (MDD; ClinicalTrials.gov NCT04620759), a subset of participants (plac

    Save this paper

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →